CCL5 and neoplasm: The combination epigenetic therapy (Aza + ITF-2357) induced the increased levels of CCL5, a secreted chemokine attracting functional lymphocytes, restraining tumor growth with increased number of CD8+ T cells in mice model of NSCLC [19].